GlucoTrack Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

GlucoTrack şirketinin kazançları yıllık ortalama -1% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 12% oranında artan oldu. Gelirler yıllık ortalama 91.9% oranında azalan oldu.

Anahtar bilgiler

-1.0%

Kazanç büyüme oranı

29.2%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	8.9%
Gelir büyüme oranı	-91.9%
Özkaynak getirisi	n/a
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

GlucoTrack to start R&D program for glucose monitoring system

Oct 10

Gelir ve Gider Dağılımı

GlucoTrack nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:GCTK Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	0	-15	4	10
30 Jun 24	0	-12	3	9
31 Mar 24	0	-10	3	6
31 Dec 23	0	-8	2	5
30 Sep 23	0	-7	2	4
30 Jun 23	0	-6	2	2
31 Mar 23	0	-5	2	2
31 Dec 22	0	-4	2	2
30 Sep 22	0	-5	3	2
30 Jun 22	0	-5	2	2
31 Mar 22	0	-4	2	2
31 Dec 21	0	-4	2	2
30 Sep 21	0	-3	2	1
30 Jun 21	0	-3	2	1
31 Mar 21	0	-3	2	1
31 Dec 20	0	-3	2	1
30 Sep 20	0	-2	1	2
30 Jun 20	0	-3	1	2
31 Mar 20	0	-3	2	2
31 Dec 19	0	-4	2	2
30 Sep 19	0	-35	2	2
30 Jun 19	0	-37	2	3
31 Mar 19	0	-38	3	3
31 Dec 18	0	-40	4	3
30 Sep 18	1	-11	6	3
30 Jun 18	1	-11	7	3
31 Mar 18	1	-11	7	3
31 Dec 17	1	-12	8	3
30 Sep 17	0	-10	7	2
30 Jun 17	0	-9	5	2
31 Mar 17	1	-8	4	3
31 Dec 16	1	-6	3	3
30 Sep 16	0	-6	3	3
30 Jun 16	0	-6	3	3
31 Mar 16	0	-6	3	2
31 Dec 15	0	-6	2	2
30 Sep 15	0	-5	2	2
30 Jun 15	0	-5	2	2
31 Mar 15	0	1	2	2
31 Dec 14	0	2	2	2
30 Sep 14	0	-5	2	2
30 Jun 14	0	-5	1	2
31 Mar 14	0	-10	1	2

Kaliteli Kazançlar: GCTK şu anda kârlı değil.

Büyüyen Kar Marjı: GCTK şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: GCTK kârlı değildir ve zararlar son 5 yılda yılda 1% oranında artmıştır.

Büyüme Hızlandırma: GCTK 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: GCTK kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 10.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: GCTK 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

GlucoTrack Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million.

Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors

GlucoTrack, Inc. announced that it has received $0.1 million in funding

Glucotrack Announces the Appointment of Andy Balo to Board of Directors

Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor

Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor

GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance Period

Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study

Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Requirement

GlucoTrack, Inc. announced that it has received $0.5 million in funding

GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring

Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor

GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024

Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors

GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor

GlucoTrack, Inc. Announces Executive Changes

Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee

Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor

GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2)

Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain Compliance

Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring System

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022

Integrity Applications, Inc. announced delayed 10-Q filing

Integrity Applications, Inc. announced delayed annual 10-K filing

Integrity Applications, Inc. Announces Executive Changes

Integrity Applications Appoints Paul V. Goode to Board of Directors

Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020

Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin